Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay

Journal of Veterinary Internal Medicine

Volumn 29, Issue 1, 2015, Pages 171-179

  Fox, P R ^a   Oyama, M A ^b   Hezzell, M J ^b   Rush, J E ^c   Nguyenba, T P ^d   Defrancesco, T C ^e   Lehmkuhl, L B ^d   Kellihan, H B ^f   Bulmer, B ^g   Gordon, S G ^h   Cunningham, S M ^c   Macgregor, J ⁱ   Stepien, R L ^f   Lefbom, B ^j   Adin, D ^d   Lamb, K ^k  

^a ANIMAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TUFTS UNIVERSITY   (United States)

^d MedVet Medical and Cancer Center for Pets   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g OREGON STATE UNIVERSITY   (United States)

^h TEXAS A AND M UNIVERSITY   (United States)

ⁱ InTown Veterinary Group   (United States)

^j Chesapeake Veterinary Cardiology Associates   (United States)

^k Lamb Statistical Consulting   (United States)

more..

Author keywords

Biomarkers; Canine; Heart disease; Respiratory distress

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ANIMAL; BLOOD; CLASSIFICATION; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DOG; DOG DISEASE; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; MALE; METABOLISM; MULTICENTER STUDY; PROCEDURES; VETERINARY;

ANIMALS; CROSS-SECTIONAL STUDIES; DOG DISEASES; DOGS; DYSPNEA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84921494982     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12472     Document Type: Article

References (36)

1. Christenson ES, Collinson PO, Defilippi CR, et al. Heart failure biomarkers at point-of-care: Current utilization and future potential. Expert Rev Mol Diagn 2014;47:327-337.
2. Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptide-guided heart failure management. Eur Heart J 2014;35:16-24.
3. Oyama MA, Boswood A, Connolly DJ, et al. Clinical usefulness of an assay for measurement of circulating N-terminal pro-B type natriuretic peptide concentration in dogs and cats with heart disease. J Am Vet Med Assoc 2013;243:71-82.
4. Prosek R, Sisson DD, Oyama MA, et al. Distinguishing cardiac and noncardiac dyspnea in 48 dogs using plasma atrial natriuretic factor, B-type natriuretic factor, endothelin, and cardiac troponin-I. J Vet Intern Med 2007;21:238-242.
5. DeFrancesco TC, Rush JE, Rozanski EA, et al. Prospective clinical evaluation of an ELISA B-type natriuretic peptide assay in the diagnosis of congestive heart failure in dogs presenting with cough or dyspnea. J Vet Intern Med 2007;21:243-250.
6. Fine DM, DeClue AE, Reinero CR. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc 2008;232:1674-1679.
7. Ettinger SJ, Farace G, Forney SD, et al. Evaluation of plasma N-terminal pro-B-type natriuretic peptide concentrations in dogs with and without cardiac disease. J Am Vet Med Assoc 2012;240:171-180.
8. Oyama MA, Rush JE, Rozanski EA, et al. Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. J Am Vet Med Assoc 2009;235:1319-1325.
9. Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008;232:1496-1503.
10. Reynolds CA, Brown DC, Rush JE, et al. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: The PREDICT cohort study. J Vet Cardiol 2012;14:193-202.
11. Häggström J, Hansson K, Kvart C, et al. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease. J Vet Cardiol 2000;2:7-16.
12. Greco DS, Biller B, Van Liew CH. Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 2003;44:293-297.
13. Tarnow I, Olsen LH, Kvart C, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009;180:195-201.
14. Moonmart W, Boswood A, Luis Fuentes V, et al. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010;51:84-96.
15. Singletary GE, Morris NA, O'Sullivan LM, et al. Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers. J Vet Intern Med 2012;26:1330-1336.
16. Wess G, Butz V, Mahling M, et al. Evaluation of N-terminal pro-B type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman Pinschers. Am J Vet Res 2011;72:642-649.
17. Schober KE, Hart TM, Stern JA, et al. Effects of treatment on respiratory rate, serum natriuretic peptide concentration and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 2011;239:468-479.
18. International Small Animal Cardiac Health Council. Recommendations for the Diagnosis and Treatment of Heart Failure in Small Animals. Woodbridge, NJ: ISACHC Publication; 1994:5.
19. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009;23:1142-1150.
20. Cui H, Huo G, Liu L, et al. Association of cardiac and renal function with extreme N-terminal fragment pro-B-type natriuretic peptide levels in elderly patients. BMC Cardiovasc Disord 2012;12:57
21. Law C, Glover C, Benson K, et al. Extremely high brain natriuretic peptide does not reflect the severity of heart failure. Congest Heart Fail 2010;16:221-225.
22. Nakayama H, Nakayama T, Hamlin RL. Correlation of cardiac enlargement as assessed by vertebral heart size and echocardiographic and electrocardiographic findings in dogs with evolving cardiomegaly due to rapid ventricular pacing. J Vet Intern Med 2001;15:217-221.
23. Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993;7:247-252.
24. Rishniw M, Erb HN. Evaluation of four 2-dimensional echocardiographic methods of assessing left atrial size in dogs. J Vet Intern Med 2000;14:429-435.
25. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 1999;13:440-447.
26. Schober KE, Baade H. Doppler echocardiographic prediction of pulmonary hypertension in west highland white terriers with chronic pulmonary disease. J Vet Intern Med 2006;20:912-920.
27. Chetboul V, Serres F, Tissier R, et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009;23:984-994.
28. Boswood A, Dukes-McEwan J, Loureiro J, et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract 2008;49:26-32.
29. Guglin M, Hourani R, Pitta S. Factors determining extreme brain natriuretic peptide elevation. Congest Heart Fail 2007;13:136-141.
30. Popat J, Rivero A, Pratap P, et al. What is causing extremely elevated amino terminal brain natriuretic peptide in cancer patients? Congest Heart Fail 2013;19:143-148.
31. Raffan E, Loureiro J, Dukes-McEwan J, et al. The cardiac biomarker NT-proBNP is increased in dogs with azotemia. J Vet Intern Med 2009;23:1184-1189.
32. Miyagawa Y, Tominaga Y, Toda N, et al. Relationship between glomerular filtration rate and plasma N-terminal pro B-type natriuretic peptide concentrations in dogs with chronic kidney disease. Vet J 2013;197:445-450.
33. Kellihan HB, Mackie BA, Stepien RL. NT-proBNP, NT-proANP and cTnI concentrations in dogs with pre-capillary pulmonary hypertension. J Vet Cardiol 2011;13:171-182.
34. Kellihan HB, Oyama MA, Reynolds CA, et al. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol 2009;11:S93-S97.
35. Bruins S, Fokkema MR, Römer JW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-2058.
36. Sjöstrand K, Wess G, Ljungvall I, et al. Breed differences in natriuretic peptides in healthy dogs. J Vet Intern Med 2014;28:451-457.